Eli Lilly to buy genetic medicine developer Akouos for $487 million
reuters.com
news
2022-10-18 11:20:50

An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. REUTERS/Mike SegarOct 18 (Reuters) - Drugmaker Eli Lilly and Co (LLY.N) will acquire genetic medicine developer Akouos Inc (AKUS.O) in a cash deal worth about $487 million.Lilly will also pay Akouos' shareholders an additional amount contingent on certain events related to its trials, which will take the total size of the deal to up to $610 million.(This story has corrected paragraph 2 to say the deal would be valued at $610 million on achieving certain milestones, not that milestone-based payments are valued at $610 million)Register now for FREE unlimited access to Reuters.
